Hepatitis New

Daclafab 60mg tablets?

Daclafab is an innovative antiviral drug. The active substance Daclatasvir (60 
mg) is an inhibitor of the nonstructural protein 5A (NS5A). The drug is used with an NS5Binhibitor, so Daclafab buy in Moscow is recommended in combination with Sofosbuvir.

Daclafab is a licensed generic drug. It is produced by several 
pharmaceutical companies, including Natco Pharma (India), accordingly the price of Daclatasvir may 
vary.

Description?

Daclafab is an inhibitor of the viral (hepatitis C virus) protein NS5A, which is used in the replication of hepatitis C virus within the liver cells (hepatocytes) and, thus, prevents the virus from entering infected hepatocytes into the blood. Thanks to this action, it is possible to prevent the spread of the virus in the body. 

Daclafab (Daclatasvir) is a highly specific direct action agent against hepatitis C virus (HCV) and does not have a pronounced activity against other RNA and DNA containing viruses, including human immunodeficiency virus (HIV). 

Daclafab (Daclatasvir) is an inhibitor of the non-structural protein 5A (NS5A), a multifunctional protein required for HCV replication, and thus suppresses two stages of the life cycle of the virus-viral RNA replication and virion assembly.

Based on in vitro data and computer simulation data, it has been shown that Daclatasvir interacts with the N-terminus within domain 1 of the protein, which can cause structural distortions that interfere with the function of the NS5A protein. 

It was found that the preparation is a potent phenotypic inhibitor of the hepatitis C virus replication of the genotypes 1a, 1b, 2a, 3a, 4a, 5a and 6a with effective concentrations (50% reduction, EC50) from picomolar to low nanomolar.

INDICATIONS FOR USE?

Treatment of chronic hepatitis C in patients with compensated liver disease 
(including cirrhosis) in the following combinations of Daclatasvir: 
- with the preparation of Sofosbuvir for patients with the hepatitis virus of genotypes 1, 3, 4, 5; 
- with the drug asunaprevir for patients with the hepatitis virus of genotype 1b; 
- with drugs asunaprevir, peginterferon alfa, and ribavirin - for patients with the 
hepatitis virus of genotype 1.

DOSAGE AND ADMINISTRATION? 

The recommended dose of Daclafab (Daclatasvir) is 60 mg once daily, regardless of food
intake. The drug should be used in combination with other medicines. Therapy is recommended for patients who have not previously received treatment for chronic hepatitis C, and with the previous ineffectiveness of therapy.

STORAGE CONDITIONS?

At a temperature not exceeding 30 ° C. 

• Delivery Time: 7 to 14 days